ABSTRACT
In cancer research and personalized medicine, new tissue culture models are needed to better predict the response of patients to therapies. With a concern for the small volume of tissue typically obtained through a biopsy, we describe a method to reproducibly section live tumor tissue to submillimeter sizes. These micro-dissected tissues (MDTs) share with spheroids the advantages of being easily manipulated on-chip and kept alive for periods extending over one week, while being biologically relevant for numerous assays. At dimensions below ~420 µm in diameter, as suggested by a simple metabolite transport model and confirmed experimentally, continuous perfusion is not required to keep samples alive, considerably simplifying the technical challenges. For the long-term culture of MDTs, we describe a simple microfluidic platform that can reliably trap samples in a low shear stress environment. We report the analysis of MDT viability for eight different types of tissues (four mouse xenografts derived from human cancer cell lines, three from ovarian and prostate cancer patients, and one from a patient with benign prostatic hyperplasia) analyzed by both confocal microscopy and flow cytometry over an 8-day incubation period. Finally, we provide a proof of principle for chemosensitivity testing of human tissue from a cancer patient performed using the described MDT chip method. This technology has the potential to improve treatment success rates by identifying potential responders earlier during the course of treatment and providing opportunities for direct drug testing on patient tissues in early drug development stages.
Subject(s)
Antineoplastic Agents/pharmacology , Drug Evaluation, Preclinical/methods , Lab-On-A-Chip Devices , Microdissection , Neoplasms/drug therapy , Neoplasms/pathology , Precision Medicine , Tissue Culture Techniques/instrumentation , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/therapeutic use , Flow Cytometry , Humans , Mice , Microscopy, ConfocalABSTRACT
Effective treatments for androgen-independent prostate cancer (AIPCa) are lacking. To address this, emerging therapeutics such as proteasome inhibitors are currently undergoing clinical trials. Inositol hexakisphosphate (IP6) is an orally non-toxic phytochemical that exhibits antitumour activity against several types of cancer including PCa. We have previously shown that treatment of PC3 cells with IP6 induces the transcription of a subset of nuclear factor-kappaB (NF-kappaB)-responsive and pro-apoptotic BCL-2 family genes. In this study, we report that although NF-kappaB subunits p50/p65 translocate to the nucleus of PC3 cells in response to IP6, inhibition of NF-kappaB-mediated transcription using non-degradable inhibitor of kappaB (IkappaB)-alpha does not modulate IP6 sensitivity. Treatment with IP6 also leads to increased protein levels of PUMA, BIK/NBK and NOXA between 4 and 8 h of treatment and decreased levels of MCL-1 and BCL-2 after 24 h. Although blocking transcription using actinomycin D does not modulate PC3 cell sensitivity to IP6, inhibition of protein translation using cycloheximide has a significant protective effect. In contrast, blocking proteasome-mediated protein degradation using MG-132 significantly enhances the ability of IP6 to reduce cellular metabolic activity in both PC3 and DU145 AIPCa cell lines. This effect of combined treatment on mitochondrial depolarisation is particularly striking and is also reproduced by another proteasome inhibitor (ALLN). The enhanced effect of combined MG132/IP6 treatment is almost completely inhibited by cycloheximide and correlates with changes in BCL-2 family protein levels. Altogether these results suggest a role for BCL-2 family proteins in mediating the combined effect of IP6 and proteasome inhibitors and warrant further pre-clinical studies for the treatment of AIPCa.
Subject(s)
Anticarcinogenic Agents/pharmacology , Apoptosis/drug effects , Phytic Acid/pharmacology , Prostatic Neoplasms/drug therapy , Protease Inhibitors/pharmacology , Androgens/metabolism , Cell Line, Tumor , Humans , Male , Prostatic Neoplasms/metabolismABSTRACT
The exopolysaccharide (EPS) biosynthesis gene clusters of four Lactobacillus rhamnosus strains consist of chromosomal DNA regions of 18.5 kb encoding 17 ORFs that are highly similar among the strains. However, under identical conditions, EPS production varies considerably among these strains, from 61 to 1611 mg l(-1). Fifteen genes are co-transcribed starting from the first promoter upstream of wzd. Nevertheless, five transcription start sites were identified by 5'-RACE PCR analysis, and these were associated with promoter sequences upstream of wzd, rmlA, welE, wzr and wzb. Six potential glycosyltransferase genes were identified that account for the assembly of the heptasaccharide repeat unit containing an unusually high proportion of rhamnose. Four genes involved in the biosynthesis of the sugar nucleotide precursor dTDP-L-rhamnose were identified in the EPS biosynthesis locus, which is unusual for lactic acid bacteria. These four genes are expressed from their own promoter (P2), as well as co-transcribed with the upstream EPS genes, resulting in coordinated production of the rhamnose precursor with the enzymes involved in EPS biosynthesis. This is believed to be the first report demonstrating that the sequence, original organization and transcription of genes encoding EPS production are highly similar among four strains of Lb. rhamnosus, and do not vary with the amount of EPS produced.
Subject(s)
Genes, Bacterial , Lactobacillus/genetics , Polysaccharides, Bacterial/biosynthesis , Polysaccharides, Bacterial/genetics , Base Sequence , DNA, Bacterial/chemistry , DNA, Bacterial/genetics , Glycosyltransferases/genetics , Lactobacillus/metabolism , Molecular Sequence Data , Multigene Family , Nucleoside Diphosphate Sugars/genetics , Open Reading Frames , Polysaccharides, Bacterial/chemistry , Promoter Regions, Genetic , Sequence Analysis, DNA , Thymine Nucleotides/genetics , Transcription Initiation Site , Transcription, GeneticABSTRACT
AIMS: Nuclease secretion was evaluated for five species of Lactobacillus and the activity was characterized in terms of thermal resistance, molecular weight and mode of action on plasmid DNA. METHODS AND RESULTS: Assays of nuclease from L. rhamnosus ATCC 9595 on DNA of different origins indicates a broad activity spectrum. Secreted nuclease from this strain resists a thermal treatment of 20 min at 100 degrees C, is not sensitive to a treatment for disruption of disulphide bonds nor to EDTA treatment under 10 mM l(-1). Nuclease production is not growth linked and seems to be constitutive. Extracellular nuclease of L. rhamnosus ATCC 9595 introduces a single-stranded nick in supercoiled DNA, thus potentially reducing the transformability of plasmid DNA. In seven of eight tested strains, SDS-PAGE revealed a major protein with a molecular weight of ca 35 kDa. Minor degradation products also showed nuclease activity. CONCLUSIONS: A comparative analysis of the extracellular fractions of 14 different Lactobacillus strains indicate that nuclease secretion seems to be a widely distributed function among species of milk-related lactobacilli. The production of secreted nuclease may contribute to the low ability of Lactobacillus spp. to be transformed and maintain exogenous DNA. SIGNIFICANCE AND IMPACT OF THE STUDY: Determination of the characteristics and distribution of nuclease activity contribute to developing strategies to overcome this barrier to efficient transformation of milk lactobacilli.